揭示 CD40 激动剂增强免疫检查点阻断的潜力。
Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade.
机构信息
The Ohio State University James Comprehensive Cancer Center and Division of Medical Oncology, Columbus, Ohio.
UPMC Hillman Cancer Center and the University of Pittsburgh Department of Medicine, Pittsburgh, Pennsylvania.
出版信息
Clin Cancer Res. 2024 Jan 5;30(1):9-11. doi: 10.1158/1078-0432.CCR-23-2437.
Abstract
In this CCR Translations, we discuss the therapeutic potential of CD40 agonism, which stimulates antigen-presenting cells (APC) to activate effector T and NK cells. CD40 agonism may lead to development of an interferon-activated, T cell-inflamed tumor microenvironment and has the potential to facilitate long-term response with immune checkpoint blockade. See related article by Weiss et al., p. 74.
摘要
在 CCR 翻译中，我们讨论了 CD40 激动剂的治疗潜力，它可以刺激抗原呈递细胞 (APC) 激活效应 T 和 NK 细胞。CD40 激动剂可能导致干扰素激活、T 细胞浸润的肿瘤微环境的发展，并有可能通过免疫检查点阻断促进长期反应。详见 Weiss 等人的相关文章，第 74 页。
相似文献
1
Uncovering the Potential of CD40 Agonism to Enhance Immune Checkpoint Blockade.揭示 CD40 激动剂增强免疫检查点阻断的潜力。
Clin Cancer Res. 2024 Jan 5;30(1):9-11. doi: 10.1158/1078-0432.CCR-23-2437.
2
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.CD40 介导的免疫细胞激活增强了抗 PD-1 在小鼠肝内胆管癌中的反应。
J Hepatol. 2021 May;74(5):1145-1154. doi: 10.1016/j.jhep.2020.11.037. Epub 2020 Dec 1.
3
Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40 monocyte differentiation.代谢相关危险信号诱导的免疫反应及反向免疫检查点激活的CD40单核细胞分化。
J Hematol Oncol. 2017 Jul 24;10(1):141. doi: 10.1186/s13045-017-0504-1.
4
Defective Th1 and Th2 cytokine synthesis in the T-T cell presentation model for lack of CD40/CD40 ligand interaction.在T-T细胞呈递模型中，由于缺乏CD40/CD40配体相互作用，Th1和Th2细胞因子合成存在缺陷。
Eur J Immunol. 1998 Nov;28(11):3552-63. doi: 10.1002/(SICI)1521-4141(199811)28:11<3552::AID-IMMU3552>3.0.CO;2-X.
5
Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells.抗原呈递细胞上的CD40触发诱导人自然杀伤细胞介导的细胞毒性作用。
Cell Immunol. 2003 Feb;221(2):81-8. doi: 10.1016/s0008-8749(03)00060-1.
6
The role of CD40 ligand in costimulation and T-cell activation.CD40配体在共刺激和T细胞活化中的作用。
Immunol Rev. 1996 Oct;153:85-106. doi: 10.1111/j.1600-065x.1996.tb00921.x.
7
Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.肿瘤细胞中 RAS/RAF/PI3K 通路抑制诱导 CD40 表达的新机制增强了对检查点阻断的反应。
Mol Cancer. 2021 Jun 6;20(1):85. doi: 10.1186/s12943-021-01366-y.
8
PKC agonism restricts innate immune suppression, promotes antigen cross-presentation and synergizes with agonistic CD40 antibody therapy to activate CD8 T cells in breast cancer.PKC 激动剂限制固有免疫抑制，促进抗原交叉呈递，并与激动性 CD40 抗体治疗协同作用，激活乳腺癌中的 CD8 T 细胞。
Cancer Lett. 2022 Apr 10;531:98-108. doi: 10.1016/j.canlet.2022.01.017. Epub 2022 Jan 21.
9
The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.人抗 CD40 激动剂抗体米妥珠单抗（ADC-1013；JNJ-64457107）激活抗原提呈细胞，改善抗原特异性 T 细胞的扩增，并增强体内模型癌症疫苗的抗肿瘤疗效。
Cancer Immunol Immunother. 2021 Dec;70(12):3629-3642. doi: 10.1007/s00262-021-02932-5. Epub 2021 May 5.
10
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).用抗 CD40 和有丝分裂纺锤体检验点控制器 BAL101553（利斯伐他汀）治疗 ICB 耐药性神经胶质瘤。
JCI Insight. 2021 Sep 22;6(18):e142980. doi: 10.1172/jci.insight.142980.
引用本文的文献
1
Advances in Cell and Immune Therapies for Melanoma.黑色素瘤的细胞与免疫疗法进展
Biomedicines. 2025 Jan 3;13(1):98. doi: 10.3390/biomedicines13010098.
2
Investigating the Use of a Liquid Immunogenic Fiducial Eluter Biomaterial in Cervical Cancer Treatment.研究液体免疫原性基准洗脱生物材料在宫颈癌治疗中的应用。
Cancers (Basel). 2024 Mar 20;16(6):1212. doi: 10.3390/cancers16061212.
本文引用的文献
1
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy.一项评估 CD40 激动性抗体 Sotigalimab（APX005M）联合 Nivolumab 治疗既往接受 PD-1 治疗后发生疾病进展的转移性黑色素瘤患者的 II 期临床试验。
Clin Cancer Res. 2024 Jan 5;30(1):74-81. doi: 10.1158/1078-0432.CCR-23-0475.
2
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.纳武利尤单抗和雷莫芦单抗治疗抗程序性死亡-1/程序性死亡配体 1 治疗后进展的晚期黑色素瘤患者：RELATIVITY-020 试验的 I/IIa 期结果。
J Clin Oncol. 2023 May 20;41(15):2724-2735. doi: 10.1200/JCO.22.02072. Epub 2023 Feb 13.
3
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.新型 4-1BB（CD137）激动剂药物在癌症免疫治疗中的新兴领域。
MAbs. 2023 Jan-Dec;15(1):2167189. doi: 10.1080/19420862.2023.2167189.
4
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.索托利单抗联合或不联合化疗一线治疗转移性胰腺癌：来自随机 2 期 PRINCE 试验的临床和免疫分析。
Nat Med. 2022 Jun;28(6):1167-1177. doi: 10.1038/s41591-022-01829-9. Epub 2022 Jun 3.
5
Site-Dependent Immune Escape Due to Impaired Dendritic Cell Cross-Priming.由于树突状细胞交叉呈递受损导致的依赖部位的免疫逃逸。
Cancer Immunol Res. 2021 Aug;9(8):877-890. doi: 10.1158/2326-6066.CIR-20-0785. Epub 2021 Jun 18.
6
Agonistic CD40 Antibodies in Cancer Treatment.癌症治疗中的激动性CD40抗体。
Cancers (Basel). 2021 Mar 15;13(6):1302. doi: 10.3390/cancers13061302.
7
Regulation of the Germinal Center Response.生殖中心反应的调节。
Front Immunol. 2018 Oct 25;9:2469. doi: 10.3389/fimmu.2018.02469. eCollection 2018.
8
Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma.一项针对转移性黑色素瘤患者的I期研究中，激动剂CD40抗体与CTLA-4阻断联合治疗的长期疗效。
Oncoimmunology. 2018 Aug 20;7(10):e1468956. doi: 10.1080/2162402X.2018.1468956. eCollection 2018.
9
Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma.患者转移性黑色素瘤接受 CD40 抗体治疗和转移瘤切除术，出现免疫激活和 9 年持续完全缓解。
Cancer Immunol Res. 2014 Nov;2(11):1051-8. doi: 10.1158/2326-6066.CIR-14-0154. Epub 2014 Sep 24.
10
Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells.人类组织中含有 CD141hi 交叉呈递树突状细胞，其功能与小鼠 CD103+ 非淋巴样树突状细胞具有同源性。
Immunity. 2012 Jul 27;37(1):60-73. doi: 10.1016/j.immuni.2012.04.012. Epub 2012 Jul 12.
Zotero 插件